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INTRODUCTION

The purpose of this thesis was to further elucidate the effects
and site of action of the cholinergic drugs on dopaminergic neurons in
rat striatum with the use of certain biochemical parameters which
provide an index of dopaminergic function.

The short term accumulation

of Dopa (3,4-dihydroxyphenylalanine), the immediate precursor of dopamine,
following inhibition of Dopa decarboxylase was used as an in vivo
estimate of tyrosine hydroxylase activity.

Dopac (dihydroxyphenyl-

acetic acid), a metabolite of dopamine, was measured to provide an
index of changes in the physiological activity of nigro-neostriatal
dopamine neurons

(Fig.

1).

This study investigated:

(1)

The effects of a variety of cholinergic and anticholinergic drugs
on tyrosine hydroxylase activity, responsible for the conversion
of tyrosine to Dopa in the dopamine synthetic pathway (Fig.

(2)

The possible site of action of these drugs, whether presynaptic
or a more complex neuronal feedback mechanism (Fig.

(3)

1).

2).

The possibility that an experimental animal model of Parkinson’s
Disease might respond differently from normals to the same cholin¬
ergic and anticholinergic drugs.

2
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The Extrapyramidal System:
The extrapyramidal system is responsible for control and fine
tuning of motor activity.

The basal ganglia, a primary component of

this'system, includes the corpus striatum (caudate nucleus, putamen,
and globus pallidus), the first two known collectively as the neo¬
striatum, and the amygdaloid nucleus.^

The substantia nigra, the

other major component of the extrapyramidal system,
pars compacta and the zona reticulata.

consists of the

The nigrostriatal dopaminergic

fiber system extends from the pars compacta of the substantia nigra
to the ipsilateral striatum and appears to be topographically arranged.
Each fiber has approximately 500,000 boutons to make synaptic contacts
with striatal cells.

Mid-brain lesions destroying the substantia nigra

result in signs of degeneration in between 65% and .100% of the striatal
boutons.

29

Stimulation of the substantia nigra increases release of

striatal dopamine

29

and causes an increase in dopamine biosynthesis as

a result of an activation of tyrosine hydroxylase.^

Approximately

80% of the total dopamine (DA) and homovanillic acid (HVA), a metabolite
of dopamine, in the mammalian brain is found in the caudate nucleus
and putamen.

The distribution of the dopamine synthesizing enzymes

tyrosine hydroxylase and Dopa decarboxylase is similar.

Drugs Affecting Striatal Dopaminergic Activity:

29

29

Drugs which increase dopamine or dopamine effects at receptor
sites in the striatum may act:

(1) directly - as dopamine (or Dopa

which is converted to dopamine) or apomorpnine, a specific dopamine
receptor agonist;

(2) indirectly - as amphetamines and amantidine

'

4

which cause dopamine to be released from nerve terminals; and (3) as
anticholinergics and antihistamines which may act by decreasing the
cholinergic component of a dopaminergic - cholinergic balance in the
striatum, or some may act by inhibiting the reuptake of dopamine into
synaptosomes, making more dopamine available in the synaptic cleft.
Drugs which decrease dopamine or dopamine effects at receptor
sites may act by:

(1) blocking dopamine receptor activity - as the

butyrophenones, like haloperidol, and most phenothiazines;
ing synthesis of dopamine - as a-methyl-p-tyrosine;

(2) inhibit¬

(3) inhibiting

dopamine storage and depleting synaptic vesicles - as reserpine; and
(4) degeneration of the nigrostriatal pathway - as caused by lesions
in the substantia nigra or nigrostriatal dopamine pathway, or by
6-hydroxydopamine.

f) ?

Parkinson's Disease
It is now well established that the basic abnormality in Parkin¬
son's Disease is a striatal dopamine deficiency.

The most common

etiologies are either idiopathic or post-encephalitic.

The majority

of the latter cases are thought to be a late sequela of encephalitis
lethargica, a disease caused by Von Economo's virus during the 1918
to 1926 pandemic.

Other possible causes include senile arteriosclerosis,

chronic manganese poisoning, tumor, and a reversible Parkinsonian-like
syndrome sometimes resulting from the use of neuroleptic drugs such
as reserpine, most phenothiazines, and the butyrophenones.

In all but

the neuroleptic-induced syndrome, the primary pathological abnormality

5

is degeneration of the dopamine containing cells in the pars compacta
of the substantia nigra projecting to the striatum.

29

In these patients,
29,31,56

striatal levels of dopamine and HVA are markedly decreased,

as

are the activities of the dopamine synthesizing enzymes, tyrosine hydroxylase and Dopa decarboxylase.

56

In addition, a positive correlation

exists between the degree of nigral cell loss, the degree of striatal
dopamine deficiency

56

, and the severity of the Parkinsonian symptoms

of akinesia, rigidity, and tremor.

29

That dopamine levels must fall

by 50% or more to manifest the disease clinically, suggests that milder
degrees of striatal dopamine deficiency can be compensated for functionally.

29

The reversible drug-induced Parkinson s-like syndrome

produced to varying degrees by most of the antipsychotics is a mani¬
festation of the dopamine receptor blocking ability of these drugs
rather than of an absolute striatal dopamine deficiency.

Consistent

with this is the observation that treatment with L-Dopa, which is
converted to dopamine by Dopa decarboxylase, produces marked symptomatic
improvement in Parkinson's Disease where there is an absolute dopamine
deficiency, but is of little value in treating the drug-induced
Parkinsonian syndrome where symptoms are due to receptor blockade.

23

Optimal therapy for Parkinson's Disease at present involves the use of
L-Dopa in conjunction with carbidopa, a peripheral Dopa decarboxylase
9

inhibitor.

With the combined use of these drugs less Dopa needs to

be administered, since more enters the brain, and fewer side-effects
are experienced from peripheral conversion of Dopa to dopamine.

15 23,45
*

Although L-Dopa acts by replacing the deficient neurotransmitter,

6

dopamine, it does not affect the course of Parkinson's Disease, in
that there is continued degeneration of the nigrostriatal dopamine
neurons.

29

Dopamine levels in the striatum of Parkinson's patients

can be increased 5 to 8 times with L-Dopa treatment, and levels of its
metabolite, HVA, are increased by even more.

30

HVA accumulates

throughout the brain, wherever there is Dopa decarboxylase activity,
but dopamine accumulates only in areas of dopaminergic innervation,
such as the striatum.

29 31
*

This could be due to uptake and storage

of the dopamine in the dopaminergic nerve terminals or to a depot source,
such as 3-0-methyldopa, which also increases in L-Dopa treated
patients.

29 31
*

The former, however, is more likely, as 3-0-methyldopa

increases throughout the brain,

like HVA, rather than locally, as

with dopamine.^
Another phenomenon observed in Parkinson's patients and in animals
with lesions destroying the nigrostriatal dopamine neurons may be the
development of denervation supersensitivity, an increase in dopamine
receptor sensitivity to the effects of dopamine.^^

Although patients

on L-Dopa show no difference with respect to maximal therapeutic bene¬
fit, patients with severe akinesia react more sensitively to a single
intravenous dose of L-Dopa than do patients with mild akinesia.
Patients on high doses of L-Dopa and animals after injection of high
doses of L-Dopa, develop abnormal choreiform movements due to the
increased dopamine levels, which can be eliminated by decreasing the
doses of L-Dopa.

29

During chronic treatment with L-Dopa, patients

often develop an increased sensitivity to both the therapeutic effects
and the choreiform side effects.

This effect may also be due to

7

denervation supersensitivity, resulting from continued degeneration
of the dopaminergic neurons.

29

Effects of Increased Dopaminergic Activity:

29

Increased dopaminergic activity manifests itself as locomotor
hyperactivity and stereotyped motor behavior.

This increased activity

could be produced either (1) by facilitation of excitatory systems or
(2) by removal of inhibitory influences upon such systems
tion).

The latter is most widely held to be correct.

(disinhibi-

In unanesthe¬

tized animals, the spontaneous firing rate of most caudate cells is
decreased by locally applied dopamine and by electrical stimulation
of the substantia nigra which increases release of striatal dopamine.
It is possible that the enhancement of motor activity by dopamine
agonists is due to elimination of normal striatal inhibitory impulses
which modify the "primitive motor patterns of the globus pallidus."

29

Post-Synaptic Dopamine Receptor Activation and Neuronal Feedback:
Most of the antipsychotics, the phenothiazines like chlorpromazine and the butyrophenones like haloperidol, are potent dopamine
receptor blockers.

Their ability to increase the firing rate of dopa¬

mine neurons in the pars compacts of the substantia nigra'*’ and to
increase synthesis and turnover J of dopamine is presumed to be due
to a neuronal feedback mechanism, since the effect is dependent upon
impulse flow in dopamine neurons.

Dopamine agonists, direct and

indirect, have the opposite effect upon dopamine neurons.

The agonists

8

result in decreases in the synthesis and release of dopamine, an effect
which can be blocked by the dopamine receptor blockers.

24

Presynaptic Dopamine Receptors:
The firing of dopaminergic neurons, and the synthesis and release
of dopamine, appears to be affected not only by a postsynaptic feedback
mechanism, but also by dopamine receptors located on the terminals of
the dopamine neuron itself.

Support for this comes in the findings:

(1) that dopamine receptors have been found on the cell body and den¬
drites of dopamine neurons and, therefore, may also be present along
the axon and nerve terminals, and (2)

that the presynaptic and the

postsynaptic dopamine receptors appear to respond differently to some
10
drugs.
In normal impulse flow, the action of synaptic dopamine is ter¬
minated primarily by reuptake into nerve terminals rather than by
degradation of the neurotransmitter.

Increasing the firing rate of

dopaminergic neurons, as in other types of nerves, results in a stimulus
dependent increase in synthesis and release of dopamine.
other neurons, however,

Unlike in

cessation of impulse flow in dopaminergic

neurons, induced either pharmacologically or by axotomy, leads to a
paradoxical increase in tyrosine hydroxylase activity and in dopamine
synthesis.

10 34 48
*
’

Presynaptic dopamine receptors are postulated to

be responsible, since the interruption of impulse flow excludes feedback
neuronal regulation.

The suggested mechanism is a decrease in the

release of dopamine secondary to interruption of impulse flow, leading

.

9

to a decrease in synaptic cleft dopamine available to react with the
presynaptic receptors.
The pool of dopamine in the nerve terminal is probably controlled
by a balance of release, reuptake, and synthesis.

Tyrosine hydroxylase

activity appears to be subject to end-product inhibition by this neutronal dopamine pool, such that decreased utilization leads to an in¬
creased neuronal dopamine pool, which then inhibits tyrosine hydroxy¬
lase activity and dopamine synthesis.

This end-product inhibition

appears to be dependent upon calcium influx into the neuron, which in
turn may depend upon stimulation of presynaptic dopamine receptors.
Lesions of the dopamine neurons or pharmacological treatment with GBL
(y-butyrolactone),

leads to cessation of impulse flow in the nigro-

neostriatal dopamine neurons, with a concomittant cessation of dopamine
release and calcium influx.

The result is an activation of tyrosine

hydroxylase with an increase in synthesis and in the neuronal dopamine
pool to which the tyrosine hydroxylase is no longer responsive, possi¬
bly because of the decreased influx of calcium.

The postulated role

of the presynaptic receptors is to allow calcium influx and return
some of the end-product regulation by the neuronal dopamine pool.

48

Direct dopamine agonists, as dopamine and apomorphine, do in fact
cause a partial inhibition of the lesion-induced increase in tyrosine
hydroxylase activity, presumably by allowing calcium influx through
their interaction with presynaptic dopamine receptors.

That this

inhibition of tyrosine hydroxylase activity is mediated via presynaptic
dopamine receptors is supported by the ability of dopamine receptor

10

blockers, such as haloperidol, to block the apomorphine effect.

10 34,48
*' 5

Dopamine and apomorphine have also been shown to inhibit the synthesis
of dopamine in rat striatal synaptosomes, a medium of the synaptic
terminals in which only local responses are measured.^
Further support for the role of presynaptic receptors in the
regulation of dopamine synthesis comes from the observations

(1) that

the dopamine receptor blockade with haloperidol will increase tyrosine
hydroxylase activity beyond that maximally obtained by stimulation
alone,

and (2) that iontophoretically applied dopamine to the nigro-

striatal dopamine neurons in the pars compacts inhibits firing of
the dopamine neurons, possibly by reacting with dopamine autoreceptors
on the cell body, a similar decrease in activity to that obtained with
dopamine agonists in presynaptic dopamine receptor studies.

48

Cholinergic Contribution to the Extrapyramidal System:
Cholinergic neurons appear to play an important role in the
extrapyramidal system.

The highest concentrations in the brain of

choline acatylase and acetylcholinesterase, the enzymes responsible
for synthesis and degradation, respectively, of acetylcholine are
found in the caudate and putamen.

6 36 37
*

*

Correspondingly, the caudate

contains the highest number of muscarinic receptors, with the putamen
and globus pallidus containing an intermediate amount.

26

Both afferent

nigrostriatal cholinergic fibers"^ and efferent cholinergic striatopallidal and striatonigral fibers

42

have been described.

lesions disrupting these pathways, however,

Selective

fail to significantly

decrease choline acetylase or acetylcholinesterase in the striatum,

11

suggesting that the neostriatal cholinergic system is primarily contained within the neostriatum as intemeurons.

36 37
*

Similarly, although

lower levels of these enzymes are found in the substantia nigra, the
levels are unchanged by lesions of the striatonigral pathway.

36

The

possibility, however, of substantia nigral cholinergic intemeurons
or cholinergic input from other areas of the brain still exists.
The execution of purposeful movement appears to be dependent upon
a dopmainergic - cholinergic balance within the striatum.

Acetyl¬

choline has been shown to increase, while dopamine decreases, the
spontaneous firing rate of most cells in the caudate.^

Local injec¬

tions of carbachol or physostigmine into the striatum have been shown
to decrease the circling induced in rats by dopamine.

22

Although the

ability of antipsychotic drugs to induce Parkinsonian-like symptoms
is related to their ability to block dopamine receptors, several anti¬
psychotic drugs with potent dopamine receptor blocking ability have
been found which show a much lower incidence of extrapyramidal side
effects than would be expected.
antimuscarinic properties.

These drugs were found to have

Subsequent studies demonstrated that the

greater the antimuscarinic potencies of these antipsychotic drugs,
the less the frequency of extrapyramidal side effects.

27 28 54
*
’

Anti¬

cholinergic drugs are not only very effective clinically in counter¬
acting the extrapyramidal side effects of the antipsychotics, but are
also of some benefit in Parkinson's patients and in animals with
lesions of the dopaminergic nigrostriatal pathway

23

, while cholinergic

drugs, such as physostigmine, exacerbate Parkinsonian extrapyramidal

12

symptoms.^
There is a great deal of evidence to suggest that cholinergic
nerves are not only involved in maintaining a balance with dopamine
in the striatum, but also have either direct or indirect effects upon
dopaminergic

neurons themselves.

Since dopaminergic activity within

the striatum has been found to have an inhibitory effect upon cholin¬
ergic neurons, such that an increase in dopaminergic activity is
associated with a decrease in cholinergic activity, and a decrease in
dopaminergic activity with an increase in cholinergic activity

46

, it

is not surprising that cholinergic activity in turn may affect dopa¬
minergic neurons.

Carbachol infusion into the substantia nigra leads

to similar changes as those caused by decreased impulse flow in the
nigrostriatal pathway

; that is, an increase in striatal dopamine

levels by decreasing turnover without changing synthesis.

32

Infusion

of atropine in the substantia nigra has been shown to increase both
turnover and synthesis of dopamine
impulse flow.

32

, as is found with an increase in

Further studies demonstrated that neurons in the zona

reticulata are stimulated by iontophoretie acetylcholine, an effect
which can be specifically blocked by the anticholinergic, scopolamine.
The enhanced firing of the zona reticulata cells is associated with a
reduced firing of cells in the pars compacta.

This, plus the fact

that acetylcholine has no effect when administered directly into the
pars compacta, suggests that acetylcholine may be exciting neurons in
the zona reticulata, which then form inhibitory synapses on pars
compacta cells.

46

Although these results suggest a possible role for

13

cholinergic influence in the substantia nigra, they are not consistent
with results obtained with the systemic administration of the same
cholinergic drugs.

Physostigmine,

oxotremorine, and arecoline,

given systemically, have been shown to increase release and turnover
of dopamine, as measured by HVA levels.

This effect can be counter¬

acted by the systemic administration of atropine.^^

Although some

studies investigating the effect of anticholinergic drugs on turnover
rate of dopamine have noted a significant decrease in HVA levels

41 44
’
,

most studies have found either no change or only a slight decrease (1)

2 12

in the rate of disappearance of dopamine after a-methy1-p-tyrosine *
2 12
(2) on the endogenous levels of dopamine ’
levels.

40

1

’

,

, or (3) on HVA

The results obtained from the systemic use of the cholinergic

and anticholinergic drugs are more consistent with the effects of these
drugs when given intrastriatally.

Perfusion of the caudate with ace¬

tylcholine plus physostigmine was found to increase the release of
g

dopamine , while microinjections of atropine

in the caudate were found

to have no effect on HVA levels.^
Substantial evidence has accumulated for the existence of presynaptic cholinergic receptors on adrenergic nerve terminals outside
the central nervous system.

Regulation of the release of norepineph¬

rine from adrenergic nerves by inhibitory muscarinic and stimulatory
nicotinic receptors have been demonstrated, the muscarinic receptors
being approximately 2 to 3 times more sensitive to acetylcholine than
the nicotinic receptors.

19

It is, therefore, possible that such

cholinergic presynaptic receptors may be present on dopamine terminals,

14

affecting the release of dopamine.

In support of this is the recent

finding that in striatal slices acetylcholine inhibits the release of
^H-dopamine induced by electrical or KC1 stimulation.^

These results

are similar to those found in peripheral adrenergic nerves with regard
to inhibitory muscarinic receptors.

However, it has also been demon¬

strated that perfusion of the caudate with oxotremorine or acetyl¬
choline plus physostigmine increases, rather than decreases, release
g

of striatal dopamine.

Prior to this, benztropine and other anti¬

parkinsonian anticholinergic and antihistaminic drugs were shown to
inhibit the reuptake of dopamine in striatal synaptosomes
into dopaminergic neurons in vivo.^

14,20,52

and

Since the ability to block re¬

uptake of dopamine appeared to coincide with their relative clinical
potencies in treating Parkinsonian extrapyramidal symptoms, it was
suggested that the beneficial effect of these drugs was due to their
ability to inhibit reuptake of dopamine, making more dopamine available
in the synaptic cleft,
cholinergic properties.

rather than, or in addition to, their anti¬
This is not supported clinically, however,

in that atropine and scopolamine, which are active anti-Parkinson's
agents, demonstrate little or no ability to block dopamine reuptake

20 52
’
,

and in that atropine, as well as benztropine, has been shown to poten¬
tiate the Dopa and apomorphine induced increase in locomotion in
rats.

20

Further biochemical studies also tend to support a feedback,

as opposed to a local, cholinergic mechanism for the effects seen in
dopaminergic neurons.

Anticholinergics have been shown to reduce the

phenothiazine or haloperidol induced increase in dopamine turnover,

15

as measured both by the rate of disappearance of dopamine from the
2 12
9
striatum *
and by the HVA levels.

Since this effect is seen in

the face of dopamine receptor blockade, it is presumed to take place
beyond the receptor and is postulated to involve an inhibition of
the receptor blocker induced increase in impulse flow through dopamxnergxc neurons.

12

Noradrenergic Neurons:
Although little norepinephrine is contained within the striatum,
approximately l/50th to l/100th the concentration of dopamine,

there

is some feeling that this transmitter may play an important role.
This is based upon the observations that

(1) L-Dopa which is also a

precursor of norepinephrine via dopamine is more effective in pro¬
ducing locomotor hyperactivity than apomorphine, a specific dopamine
agonist, and (2) L-Dopa is not as effective if the formation of nor¬
epinephrine by dopamine 3-hydroxylase is inhibited.

It is therefore

possible that the noradrenergic system, while not directly involved,
is playing a regulatory role in determining the sensitivity of the
extrapyramidal system to dopamine.

More work is necessary in this

area, however, before this can be established.

29

GABA-ergic Neurons:
It appears likely that GABA-ergic (gamma amino butyric acid)
neurons have an important inhibitory function in the substantia nigra
and possibly also play a role in the striatum.
ergic role in the substantia nigra includes:

Evidence for a GABA-

(1) in the brain, GABA

16

and its synthesizing enzyme,

glutamic acid decarboxylase, are found

in highest concentrations in the substantia nigra;

46

(2) lesions of

the strionigral pathway markedly decrease both GABA and glutamic
acid decarboxylase in the substantia nigra;^ (3) electrical stimula¬
tion of the caudate blocks the firing rate of nigral units in the
zona reticulata;

8

(4) iontophoretically applied GABA in the substantia

nigra invokes the same response as electrical stimulation of the
caudate, blocking the activity of cells in the zona reticulata of the
substantia nigra;

8 46
*
and (5) intravenous or substantia nigral ad¬

ministration of biculline,

a GABA receptor blocker, causes an increased

g
release of striatal dopamine.

This all lends strong support for a

strionigral GABA-ergic system inhibitory to nigrostriatal dopaminergic
neurons.
There is some evidence that GABA may also play a role in the
striatum.

Labeled GABA is taken up by receptors in the striatum,

and glutamic acid decarboxylase activity can be found in striatal
synaptosomes, establishing the presence of GABA-ergic neurons in

g
the striatum.

It has been demonstrated that GABA in the striatum

causes a decrease in the release of dopamine and that the GABA
receptor blockers, biculline and picrotoxin,

cause an increase in the

release of dopamine and are capable of counteracting the decrease
in dopamine release induced by GABA.

8

Whether these represent feed¬

back or presynaptic responses has yet to be determined.

17

FIGURE 2
MODEL OF POSSIBLE NIGROSTRIATAL NEURONAL INTERACTIONS

Motor
Activity

Ach = acetylcholine
DA = dopamine
GABA =

-aminobutyric acid

+ = excitatorv
- = inhibitory
o-o-o

= Possible Multinenronal Pathway
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EXPERIMENTAL DESIGN

Dopa Assay:

To determine the effects of cholinergic and anticholinergic
drugs on tyrosine hydroxylase activity,

the dopa decarboxylase

inhibitor, Ro 4-4602, was given to block the conversion of Dopa to
dopamine, and a modification of the method of Kehr, Carlsson, and
Lindquist was used to assay for Dopa.

33

In the normal untreated

rat brain, Dopa is rapidly converted to dopamine and endogenous Dopa
levels are very low (< 10 ng/g).

33

After Ro 4-4602,

linear increase in Dopa for up to an hour.

59

Dopa levels in an Ro 4-4602 treated rat is,

there is a

Determining striatal
therefore, a reliable

method for measuring the effects of drugs on tyrosine hydroxylase
activity in vivo, and thus of assessing the effective rate of
synthesis of dopamine.
Ro 4-4602 was given to all rats 30 min prior to kill in a dose
of 800 mg/kg, which is known to block central dopa decarboxylase
activity.

59

19

Dopa Assay using 6-Hydroxydopamine Treated Rats:

Intracistemal 6-hydroxydopamine

(6-OH DA) has been shown to

cause selective degeneration of monoaminergic neurons.

When a

norepinephrine uptake blocking drug is given prior to the 6-OH DA to
prevent its action on noradrenergic neurons, the degeneration is
specific for dopaminergic neurons.^’^'

In order to determine the

effects of physostigmine and benztropine on tyrosine hydroxylase
activity in a dopamine deficient state, such as Parkinson’s Disease,
a pilot study was carried out using 6-OH DA treated rats as an experi¬
mental animal model.
Dr. B.

The rats were obtained at 5 weeks of age from

Shaywitz, in whose lab, 2 litters of rats had been randomly

divided at 5 days of age into treated and non-treated groups.

The

treated rats had received 100 yg 6-OH DA intracistemally with the
norepinephrine uptake blocker, desmethylimipramine, 25 mg/kg intraperitoneally, being given 30 min prior to the 6-OH DA in order to
protect the noradrenergic neurons.

All rats used in this study were

taken from these same 2 litters, including 3 untreated rats as
controls.
The rats were treated identically to those used for the other
Dopa assays, receiving 800 mg/kg Ro 4-4602 30 min prior to kill.
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Dopa Assay with GBL:

Gamma butyrolactone

(GBL) has been shown to selectively block

impulse flow in central dopaminergic neurons and thus block the
release of dopamine.

The block of impulse flow produced by GBL

administration causes approximately a 3-fold increase in tyrosine
hydroxylase activity, as measured using Ro 4-4602 and the Dopa assay,
results similar to that produced by axotomy.
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By blocking impulse

flow, any change in the rate of synthesis, outside of that caused by
GBL itself, would have to be mediated locally via presynaptic
receptors on the dopaminergic nerve terminal, rather than through a
neuronal feedback mechanism.

In order to help define the site of

action of the cholinergic and anticholinergic drugs, GBL was
administered and striatal Dopa assayed as before.
All rats were given 750 mg/kg GBL at 35 min and 800 mg/kg
Ro 4-4602 at 30 min prior to kill.
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Dopac Assay:

To determine the effects of cholinergic and anticholinergic
drugs on impulse flow in dopaminergic neurons, a modification of the
method of Murphy, Robinson, and Sharman was used to measure
3,4-dihydroxyphenylacetic acid (DOPAC) in rat striatum.
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The Dopac

assay was selected rather than the measurement of HVA levels, which
has been used to measure turnover of dopamine in previous studies,
because of the more rapid and consistent response of Dopac to changes
in dopamine degradation, and because it closely reflects changes in
impulse flow in the nigrostriatal dopamine neurons.^

22

MATERIALS AND METHODS

Male Sprague Dawley

(Charles River Co., Inc.) albino rats

weighing between 150-350 gm were used.

All drugs were given by

intraperitoneal injection at times noted as minutes prior to kill.
For the Dopa assay, all rats received Ro 4-4602 at 30 min prior to
kill.

The rats were killed by decapitation and the neostriatum

(caudate and putamen) was dissected out rapidly and placed on dry
ice.

Estimations of Dopa were made on the bilateral striata of each

rat.

For the Dopac assay, estimations were also made on the

bilateral striata of each rat.
Control rats in the Dopa experiments received Ro 4-4602 and
in the Dopa experiments with GBL received Ro 4-4602 and GBL.
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Drugs used in Dopa and Dopac Experiments:

Pharmaceutical Companies

Drugs

Anticholinergics:

Atropine sulfate

Merck & Co.

Atropine methyl nitrite

K & K Laboratories

Scopolamine*HBr trihydrate

Regis Chem. Co.

Benztropine Mesylate

Merck, Sharp, & Dohme

Artane

Lederle

Cholinergics:

Physostigmine* SO

4

Calif.

Corp.

for Biochem. Research

Pilocaprine*HCl

Merck & Co.

Oxotremorine Sesquifumarate

Aldrich Chem.

Arecoline*HBr

Regis Chem.

Co.

Co.

DA Impulse Flow Blocker:

Gamma-butyrolactone (GBL)

Matheson, Coleman & Bell

Dopa decarboxylase Inhibitor:

Ro 4-4602 (s eryl-trihydro xybenzyl hydrazine)

Hoffmann-LaRoche, Inc.

24

Popa Assay:

Sample Preparation:

The caudate pairs were weighed and homogenized in 2 ml (+2 ml
more to wash the pestle and tube) of .4N PCA soln.

containing - 50 mg

Na2S20^ + 2 ml 10% EDTA + 10 ml 4N Perchloric acid - made up to
100 ml with distilled H^O

(made fresh for each experiment).

For each

tissue blank and recovery, half the cerebellum from an untreated
rat was prepared in the same way.
tissue recovery tubes.

100 ng of Dopa was added to the

The homogenates were centrifuged at

11,000 RPM and supernatants were brought to pH 2 with KOH (5N,
& .IN).

IN,

Samples were then frozen overnight at -20°C.

Column Procedure:

Preparation of Dowex 50W, X-4, 200-400 mesh, H+:

100 g of

Dowex was washed with 200 ml of 2N NaOH (containing 1% EDTA), stirring
for 10 min.

After allowing to separate, the liquid was poured off

and the wash repeated.

The Dowex was then rinsed with 1000 ml

distilled H^O in the same manner, repeating until approximately the
pH of H^O.

The Dowex was washed 3 times with 100 ml 2N HC1 and

rinsed again with 1000 ml distilled ^0 until approximately the pH
of ^0.

It was then kept stored in the refrigerator with 200 ml of

H 0 above the Dowex.

2
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Column preparation:

A 4 cm column of Dowex was made in a 50 ml

column containing a glass wool plug.
washed with ^0.

The sides of the column were

Twenty ml of 0.1N sodium phosphate buffer (pH 6.5)

with 0.1% EDTA was run through the column which was then rinsed with
5 ml of H2O.

Elution:

The samples were thawed, centrifuged at 11,000 RPM

for 10 min, and poured over the columns.

The following solutions

were run through the column and the eluates discarded:
aqueous methanol,

(2) 10 ml H^O,

phosphate buffer (pH 2.5),
citrate buffer (pH 4.5).

(3) 10 ml 0.1M sodium citrate

(4) 10 ml H^O, and (5) 1 ml 0.1M sodium
The Dopa was then eluted with 3 ml of the

sodium citrate buffer.

Fluorometric Determination of Dopa:

Amino settings:

Activating peak - 360 nm
Fluorescence peak - 480 nm

Slits:

(1) 20 ml 60%

1 - slit 4 mm at position 2
2 - 3 mm
3 - 4 mm
4— 4 mm
5- 3 mm
6 - slit 4 mm at position 2
7 - position 3

Meter multiplier - .003
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Treatment of samples:
of standards

Samples were run in duplicate with a set

(0, 10, 25, 50, & 75 ng Dopa).

The following solutions

were placed in tubes, vortexing between additions:
Na^HPO^,

(1) 0.5 ml 0.15M

(2) the appropriate amount of Dopa to the standards plus

0.5 ml of 0.1M sodium citrate,

(3) 0.5 ml sample in the appropriate

tubes,

(5) 0.05 ml 0.2% ZnSO ,
4

(4) 0.2 ml 95% ethanol,

(6) 0.05 ml

0.1% K^FeCCN)^ - addition timed so that 6 min later 0.5 ml of 5N NaOH
with 1% ascorbic acid (made fresh just prior to step #6) was added.
The samples were read between 3 min and 30 min after adding the NaOH.

Treatment of Data:

• Using the % Transmission

(T) obtained from the standards

(subtracting the blank from the standards), a graph of % T vs. ng
Dopa was plotted.

The % T of the tissue blanks

(approximately 1%

T greater than the standard blanks) was subtracted from that of the
samples and the amount of Dopa in the sample determined from the
graph.

The ng Dopa/g tissue was obtained by multiplying by 6

(to

find the total amount of Dopa eluted), and dividing by the % recovery
(usually around 60%) and by the weight of the caudates.
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Dopac Assay:

Sample preparation:

The caudate pairs were weighed and homogenized in 2 ml (+1 ml
to rinse the pestle and tube) of cold 0.1N HC1.
recoveries

Tissue blanks and

(containing 100 ng Dopac/tube) were prepared from half a

cerebellum/tube.

0.12 ml cone. PCA (perchloric acid) and approxi¬

mately 1.4 g KC1 was added to the tubes, which were then centrifuged
at 10,000 RPM for 10 min.
tubes containing 7 ml

The supernatant was poured into prechilled

butylacetate

(Baker's Superior Grade -

redistilled) and approximately 0.4 g KC1.

After capping and shaking

in the cold room for 10 min, the tubes were centrifuged in the
International Centrifuge at 15 RPM for 5 min.

Six ml of butyl-

acetate was drawn off the samples and added to tubes containing 2 ml
Soln. A (see below).

Four tubes for the standard curve were set up

containing 2 ml butyl acetate and 2 ml Soln. A.

After capping and

shaking for 6 min in the cold room, the tubes were centrifuged for
5 min at 15 in the International Centrifuge.
Soln. A:

35 ml 1^0, 1 ml 2N HC1,

1.5 ml ethylenediamine (twice distilled)

B:

6 ml 1^0, 6 ml cone. HC1

C:

18 ml H^O, 2 ml ethylenediamine (EDA, twice distilled)

Assay:

Two tubes for use in setting the amino

were prepared with
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.85 ml Soln. A and 50 ng & 100 ng Dopac, respectively.

Eight tubes for

use as standards were prepared with .85 ml of the butylacetate-Soin. A
mixtures made in the previous section (2 blanks, 2 with 25 ng Dopac,
2 with 50 ng Dopac, 1 with 75 ng Dopac, and 1 with 100 ng Dopac).
Samples were run in duplicate,

.85 ml/tube.

Marbles were used to

cover the mouths of the tubes, which were then placed in a water
bath at 60°C with a tight lid for 20 min.
ice and the bucket covered.

The tubes were placed in

Twenty-five ml of Soln.

B was added to

each of the tubes, which were then vortexed, and the bucket recovered.
After approximately 10 min, 25 ml of Soln.
vortexed, and the bucket recovered.
room in the Aminco:

C was added, the tubes

The samples were read in a dark

activating peak - 385 nm; fluorescence peak -

455 nm; using a Coming filter # 3389

(CS3-73, 1.52 min); slit

settings were the same as for the Dopa Assay: Meter multiplier - .03.

Treatment of the Data:

Using the % Transmission (T) obtained from the standards

(sub¬

tracting the blanks from the standards), a graph of % T vs. ng
Dopac was plotted, the % T of the tissue blanks was subtracted from
that of the samples, and the amount of Dopac assayed determined
from the graph.

The ng Dopac/g tissue was obtained by dividing the

ng Dopac assayed by the fraction of sample used for the assay (36.4%),
the % recovery (usually around 50%), and the weight of the caudates.

29

RESULTS

Data was analyzed using the Standard Estimate of the Mean (SEM)
and a two-tailed "t" test.
difference, while p

Dopa Assay:

p

< .05 is considered a significant

> .05 is not a significant difference.

(Tables 1 & 2; Figures 3-6)

Benztropine was found to be a potent and dose related inhibitor
of Dopa accumulation.

While artane, atropine, and scopolamine showed

only slight, if any, inhibitory properties.

All of the cholinergic

drugs tested - physostigmine, pilocarpine, oxotremorine and arecoline
significantly increased accumulation of Dopa.

A better response was

found when the drugs were given at 40 min as opposed to 45 min prior
to kill, probably due to their shorter duration of action.

All the

anticholinergic drugs, including those having only minimal effects
when used alone, successfully prevented or significantly inhibited
the physostigmine induced increase in Dopa accumulation.

The central

action of these drugs was confirmed by using atropine methylnitrite
(AMN), a peripheral anticholinergic with no central effects, which
was shown to be ineffective in preventing the physostigmine induced
increase in Dopa accumulation.

Neither atropine nor benztropine

were able to significantly affect the pilocarpine induced increase
in Dopa accumumation.
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TABLE 1
DOPA ASSAY - EFFECTS OF CHOLINERGIC AND ANTICHOLINERGIC
DRUGS USED INDIVIDUALLY

DRUG*

DOSE
(mg/kg)

n

Control

D0PA(ng/g

+

29

1033 + 34

SEM)

-H

+

/o A

P

Atropine

50

60

17

928 + 31

.05

Scopolamine

25

60

3

1042 + 79

N.S.

50

60

4

895 + 91

N.S.

15

60

4

779 + 44

.01

-25

II

30

60

5

504 + 61

II

50

60

3

387 + 33

50

60

6

863

+

1

45

11

1661

1

40

7

100

45

100

Artane
Physostigmine
If

Pilocarpine
II

Oxotremorine
Arecoline

-51

< .01

-63

86

.05

-16

+

77

< .01

+61

1898

+

142

<

.01

+84

4

1271

+

152

.04

+23

40

8

1861

+

140

<

.01

+80

3

40

3

1423 + 37

<

.01

+38

50

40

3

1411 + 126

< .01

+37

A

Benztropine

a

O
I-1

?!

-10

* All rats received 300 mg/kg Ro 4-4602 at 30 min prior to kill
min prior to kill
Dopa measured in ng/g of tissue.
Compared with the control.
Percent change in Dopa accumulation from control
Increase - +
decrease = a N.S. - Not significant at the .05 level.

**
***
+
++

31

TABLE 2
DOPA ASSAY - INHIBITION OF THE CHOLINERGIC-INDUCED INCREASE
IN DOPA ACCUMULATION BY ANTICHOLINERGIC DRUGS

n

DOPA(ng/g + SEM)***

++

11

1

40

7

1898 + 142

2174 + 190

N.S.

<.01

.05

1661 + 77

822 + 41

50/1

60/40

4

1099 + 48

Scopolamine
+ Physostigmine

25/1

60/45

3

823 + 85

Artane
+ Physostigmine

50/1

60/45

3

683 + 29

Benztropine
+ Physostigmine

15/1

60/40

3

1075 + 173

30/1

60/45

5

708 + 83

8

1861 + 140

100

40

.03

N.S,

N.S,

.02

N.S,

i—t
o

15

V

60/45

rH
o

50/1

V

Atropine
+ Physostigmine

V

3

i—i
O

60/40

Pilocarpine

P

45

25/1

II

+

1

AMN4^
+ Physostigmine

If

P

A

II

t 's

o
H*

Physostigmine

DOSES
(mg/kg)

•

DRUGS*

N.S,

Atropine
+ Pilocarpine

50/100

60/40

3

1809 + 73

N.S.

Benztropine
+ Pilocarpine

15/100

60/40

3

1728 + 31

N.S.

* All rats received 800 mg/kg Ro4-4602 at 30 min prior to kill.
** min prior to kill
*** Dopa measured in ng/g of tissue.
+ Compared with the cholinergic drug (physostigmine or pilocarpine).
++ Compared with the anticholinergic drug (atropine, scopolamine,
artane, or benztropine).
-H-4- Atropine methylnitrite, a peripheral anticholinergic which does
not enter the CNS.
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FIGURE 3

Hopa (m;/|<)

QOPA ASSAY - EFFECTS OF ANTICHOLIEERC-IC DRUGS

FIGURE

k

Dopa {lift/f? >

DOPA ASSAY - EFFECTS OF CHOLINERGIC DRUGS

Dose(m?/!<5):

1

1

100

ICO

3

50
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FIGURE 3'
DOPA ASSAY - INHIBITION OF PHY3OSTIGMU'IE-EIDUCEQ INCREASE

Dopa (nc/n)

El DOPA ACCUMULATION BY ANTICKOLETEEGIC DRUGS

FIGURE 6
DOPA ASSAY - ANTICHOLINERGIC DRUGS WITH PILOCARPINE

?ilo,

Pilo.

?ilo.
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Dopa Assay Using 6-OH DA Treated Rats:

(Table 3; Figure 7)

In this pilot study, it was found that the Dopa accumulation in
the 6-OH DA treated control rats was only about 50% that of their
untreated littermates.

With regard to drug effects in the 6-OH DA

treated rats, benztropine produced a significant decrease, while
physostigmine was found to produce no significant change in Dopa
accumulation from that of the 6-OH DA control rats.

TABLE 3
DOPA ASSAY - USING 6-OH DA TREATED RATS

L/v7 J JL

i

t

n

D0PA(ng/g + SEM)

1313

p

p^

-O

(mg/kg)

1+

,

DRUG

Control

3

6-OH DA Control

3

638 ± 35

<.01

6-OH DA/Phys.

1

45

3

590 ± 35

N.S.

6-OH DA/Benz.

10

60

3

364 ± 16

<.01

* All rats received 800 mg/kg Ro4-4602 at 30 min prior to kill.
** min prior to kill
*** Dopa measured in ng/g of tissue.
+ Compared with control.
4+ Compared with 6-OH DA control.
+++ Percent change in Dopa accumulation from 6-OH DA.
Decrease = -

-43

i
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FIGURE 7

Do pa (nf;/fi)

DOPA ASSAY USING 6-CH DA TREATED RATS

Control

6-CH DA
Control

6-OH DA
+
Phys

6-OH DA
+
Benz.
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Dopa Assay with GBL:

(Table 4)

After stopping impulse flow through the dopaminergic nigrostriatal
neurons with GBL, no change in the accumulation of Dopa could be
produced with either the anticholinergic drugs, atropine and benztropine,
or the cholinergic drugs, physostigmine and pilocarpine.

TABLE 4
DOPA ASSAY - AFTER TREATMENT WITH GBL

DRUG*

DOSE
(mg/kg)

**
t

GBL Control

n

D0PA(ng/g + SEM)''** ***

6

2548 + 104

+
P

Atropine

50

60

6

2294 + 189

N.S.

Benztropine

15

60

6

2677 + 176

N.S.

1

40

6

2457 + 293

N.S.

100

40

3

2547 + 230

N.S.

Physostigmine
Pilocarpine

* All rats received 750 mg/kg GBL at 35 min and 800 mg/kg Ro4-4602
at 30 min prior to kill.
** min prior to kill
*** Dopa measured in ng/g of tissue.
+ N.S. - Not significant at the .05 level as compared with the GBL
control.
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Dopac Assay;

(Table 5; Figure 3)

The cholinergic drugs, physostigmine and pilocarpine,

caused a

significant: increase in Dopac levels in the striatum, while the
anticholinergic drugs, atropine and benztropina, had no significant
effect on Dopac levels.

From the graph it appeared that benztropine

was more effective in countering the physostigioine induced increase
in Dopac, while atropine was more effective in countering the pilo¬
carpine induced increase in Dopac; however, after statistical analysis,
all that could be said was that the physostigmine, but not the pilo¬
carpine, induced increase in Dopac could be inhibited by benztropine.
Atropine did not produce a statistically significant inhibition of
either the physostigmine or the pilocarpine induced increase in Dopac.

FIGURE 8
DOFAC. ASSAY

<•

f
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TABLE 5
DOPAC ASSAY

DRUGS* **

DOSES
(mg/kg)

Control

& 'k
n

DOPAC (ng/g + SEM)

6

1218 + 66

+
P

-HP

P

+++

c/
/oA* "t*

Atropine

50

4

1148 + 64

N.S.

Benztropine

20

8

1192 + 37

N.S.

1

8

1879 + 92

<.01

+54

100

3

1770 + 173

.02

+45

Atropine
+ Physostigmine 50/1

4

1588 + 141

N.S.

,05

Benztropine
+ Physostigmine 20/1

4

1294 + 77

<.01

N.S.

Atropine
+ Pilocarpine

50/100

4

1285 + 84

N.S.

N.S.

Benztropine
+ Pilocarpine

20/100

3

1614 + 58

N.S.

<.01

Physo s tigmine
Pilocarpine

* The anticholinergic drugs (atropine and benztropine) were given at
60 min prior to kill, and the cholinergic drugs (physostigmine and
pilocarpine) were given at 40 min prior to kill.
** Dopac was measured in ng/g of tissue.
+ Compared with control.
++ Compared with the cholinergic drug,
+++ Compared with the anticholinergic drug.
t Percent change in Dopac accumulation from control.
Increase ~ +
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DISCUSSION

The administration of a variety of cholinergic drugs, including
physostigmine, pilocarpine, arecoline, and oxotremorine,
produced an increase in dopaminergic activity.

consistently

This stimulation of

dopaminergic activity by cholinergic drugs involved both an increase
in tyrosine hydroxylase activity,as measured by Dopa accumulation,
and an increase in impulse flow,as measured by Dopac accumulation
(with physostigmine and pilocarpine).

The increase in synthesis demon¬

strated in this study is consistent with the recent observation by Ulus
and Wurtman, Dec.

1976, that choline administration, which increases

acetylcholine levels,

results in an increase in tyrosine hydroxylase

...
.58
activity m rat striata.
While the anticholinergic drugs, atropine, scopolamine, and artane,
had either no effect or caused only a slight decrease in tyrosine
hydroxylase activity whan used alone, they all significantly inhibited
the physostigmine-induced increase in tyrosine hydroxylase activity.
Since this effect is seen with several anticholinergics, including
atropine, which is a specific muscarinic blocking agent, the mechanism
of action is most likely due to a blocking of the effects of the in¬
creased muscarinic cholinergic activity produced by physostigmine.
The failure of these anticholinergic drugs to decrease tyrosine
hydroxylase activity significantly in the absence of an initial choli¬
nergic stimulus to increase tyrosine hydroxylase activity, suggests a
normally low cholinergic component to the striatal dopaminergic - cho¬
linergic balance.

If the cholinergic contribution is normally low,
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the anticholinergic drugs would be expected to have little or no effect.
This is also consistent with the observation that anticholinergic drugs
appear to inhibit the increase in dopaminergic activity induced by antipsychotic drugs.

2 9 12
’ ’

cholinergic activity

46

Since dopamine has been shown to inhibit striatal
, blockade of dopamine receptors by the antipsy¬

chotic drugs would release the cholinergic neurons from inhibition and
lead to an increase in cholinergic activity.

This increase in choli¬

nergic activity would result in, or at least contribute to, the increase
in dopaminergic activity seen following the administration of the anti¬
psychotic drugs.

By blocking this increase in cholinergic effects, the

anticholinergic drugs would, therefore, also be expected to inhibit
the antipsychotic-induced increase in dopaminergic activity.

This

concept of a dopaminergic - cholinergic balance such that dopamine
plays a primary tonic inhibitory role is also supported by the beha¬
vioral observation that the dyskinesia associated with intrastriatal
dopamine is counteracted by cholinergic drugs, but is not made more
severe by pretreatment with atropine.

13

There are two possible explanations for the ability of benztropine,
but not the other anticholinergics, to decrease tyrosine hydroxylase
activity.

First, benztropine may be a more potent anticholinergic

23

,

and thus higher doses of the other anticholinergics would be needed
to display the same inhibitory effect produced by benztropine-.

The

other, and more likely, possibility is that benztropine affects tyrosine
hydroxylase activity by a direct effect, independent of its cholinergic
properties.

This was suggested by Coyle and Snyder (1969) in their
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study of the effects of benztropine on reuptake of dopamine into striatal
synaptosomes.

14

It is still, therefore, possible that this effect is

being mediated through benztropine's ability to decrease reuptake of
dopamine, making more dopamine available at the postsynaptic receptor.
This additional action of benztropine may also explain why benztropine
is clinically more effective than the other anticholinergic drugs in
counteracting Parkinsonian extrapyramidal symptoms.
That neither atropine nor benztropine was able to inhibit the
pilocarpine induced increase in tyrosine hydroxylase activity implies
either a direct pilocarpine effect, independent of its cholinergic
properties, or a more potent cholinergic effect, which was not counter¬
acted by the anticholinergics in the doses used in this study.

Although,

peripherally, pilocarpine has been found to have a complex mixture of
nicotinic as well as muscarinic responses

23

, it is doubtful that the

effects in this study were being produced by stimulation of nicotinic
receptors.

If nicotinic receptors played a role in the stimulation

of tyrosine hydroxylase activity, physostigmine, which increases
acetylcholine at the receptor site by inhibiting acetylcholinesterase,
would also be expected to have both muscarinic and nicotinic effects.
Since atropine, a specific muscarinic receptor blocker, was able to
totally block the physostigmine-induced increase in tyrosine hydroxy¬
lase activity, stimulation of nicotinic receptors
of major importance.

was

apparently not

Pilocarpine does seem to have a cholinergic

action which is not countered by atropine administration, since the
activity of cholinergic neurons remains depressed even after atropine

42

administration.In addition to its central cholinergic effects,
such as cortical arousal in cats, which can be blocked by atropine,
pilocarpine has been found to have some strychnine-like effects.

23

It is uncertain, however, what part, if any, this plays in the response
seen in this study.
The absence of any effect on tyrosine hydroxylase activity with
the cholinergic and anticholinergic drugs after treatment with GBL to
block impulse flow through the dopaminergic neurons makes the possi¬
bility of a major presynaptic site of action for these drugs unlikely,
at least when they are given systemically.
results of the Dopac assay.

This is supported by the

The cholinergic drugs, physostigmine and

pilocarpine, which had produced increases in tyrosine hydroxylase
activity, also produced increases in impulse flow in the dopamine
neurons.

Atropine had no significant effect on either impulse flow

or on tyrosine hydroxylase activity.

These results suggest that the

stimulation of tyrosine hydroxylase activity by cholinergic drugs
involves the intact dopamine neuron and is via increased impulse flow
rather than through presynaptic receptors.
It has been demonstrated that microinjections of carbachol into
the substantia nigra inhibit dopamine turnover and have no effect on
synthesis, while atropine in the substantia nigra increases turnover.
These results are opposite to those found following the systemic use
of the same drugs.

it is therefore unlikely that the substantia

nigra is the major site of action of the systemically administered
cholinergic and anticholinergic drugs.

On the other hand, perfusion

32
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of the caudate with acetylcholine plus physostigmine or with oxotreg
morine alone was found to increase the release of dopamine

and micro¬

injections of atropine into the caudate were found to have no effect
on HVA levels.

40

These results are more consistent with the effects

following the systematic use of these drugs.

Although these findings

suggest that the major site of action of the cholinergic and anti¬
cholinergic drugs is in the striatum with a feedback loop to the dopa¬
mine neurons in the substantia nigra, an extra-striatal site of action
for these drugs cannot be ruled out.

It is also still possible that

local acetylcholine in both the striatum and the substantia nigra may
play a role in normal regulation of dopaminergic activity, since the
effects of systemic cholinergic and anticholinergic drugs may have a
lower affinity for these regions of the brain, or may have more dif¬
ficulty gaining access to these sites as the result of local blood
supply or diffusion.
The results of the Dopac experiments in which the cholinergic
drugs, physostigmine and pilocarpine, were given in conjunction with
the anticholinergic drugs, atropine and benztropine, are difficult to
interpret.

The expected result was that the anticholinergic drugs

would at least counteract the increase in Dopac seen with physostig¬
mine.

This was, in fact, the case with benztropine, which did cause

a statistically significant inhibition of the physostigmine induced
increase in Dopac.

However, because of the relatively greater range

of error encountered in the Dopac experiments, as compared to the Dopa
assays, no statistically significant change from the cholinergic-induced
increase in Dopac could be seen after the addition of atropine to
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physostigmine or either atropine or benztropine to pilocarpine treatment.
The pilot study using rats which had been treated with intracistemal 6-hydroxydopamine in conjunction with intraperitoneal desmethylimipramine, to cause a selective degeneration of dopaminergic
neurons, showed a decrease of approximately 50% in Dopa accumulation
as compared with normal rats.

These rats showed a further decrease

in Dopa accumulation when treated with benztropine, a similar decrease
to that seen when treating normal rats with benztropine.

The 6-hydroxy¬

dopamine treated rats, however, were unable to increase tyrosine hy¬
droxylase activity when treated with physostigmine, whereas normal
rats could.

This may be a clue to the mechanism by which cholinergic

drugs are able to exacerbate Parkinson's Disease and Parkinsonian-like
movement disorders induced by neuroleptic drugs
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, while normal un¬

treated animals and people are able to compensate for these cholinergic
drug effects without the development of Parkinsonian symptoms.

In

Parkinson's Disease, where there is a degeneration of a large part of
the dopaminergic neurons, the remaining neurons may already be pro¬
ducing dopamine optimally and be unable to increase synthesis further
to compensate for the increase in cholinergic activity.

In the neuro¬

leptic induced Parkinsonian-like syndrome, where there is already an
increase in dopaminergic activity in order to compensate for the re¬
ceptor blockade^, it may be that the addition of cholinergic drugs is
unable to further stimulate dopamine production, and the balance
would thus be tipped even more in the direction of increased choli¬
nergic versus dopaminergic activity in the striatum.
remains to be tested experimentally.

This hypothesis

.
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SUMMARY

1.

Using an assay for Dopa after inhibition of Dopa decarboxylase

as a measurement of tyrosine hydroxylase activity and an assay for
Dopac as an indicator of changes in impulse flow in nigro-neostriatal
dopamine neurons,

this study has shown that the systemic administra¬

tion of cholinergic drugs stimulates dopaminergic activity.

The sys-

temically administered cholinergic drugs, physostigmine, pilocarpine,
arecoline, and oxotremorine, all significantly increased tyrosine
hydroxylase activity.

Although all of the anticholinergic drugs

tested counteracted the physcstigmine-induced increase in tyrosine
hydroxylase activity,

atropine, scopolamine, and artane, used alone,

had either no effect or only slightly decreased tyrosine hydroxylase
activity.

This observation was postulated to be due to a tonic inhi¬

bitory action of dopamine neurons on cholinergic neurons, such that
the normal cholinergic contribution in the striatum would be relatively
low as compared to that of dopamine.

Benztropine was the only anti¬

cholinergic drug which, when used alone, caused a significant and dose
related decrease in tyrosine hydroxylase activity.

This effect

was

felt to be due to benztropine's ability to inhibit reuptake of dopa¬
mine into nerve terminals, making more dopamine available at the postsynaptic receptor.

The possibility, however, that benztropine was

simply a much more potent anticholinergic than the others tested
could not be ruled out on the basis of this study.

The pilocarpine

induced increase in tyrosine hydroxylase activity was not inhibited
by either atropine or benztropine.

This pilocarpine effect was thought

■
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to be due possibly to a direct cholinergic effect of pilocarpine not
subject to atropine or benztropine inhibition.

2.

The mode of action of the cholinergic and anticholinergic drugs

was shown to be through a neuronal feedback mechanism involving the
entire dopamine neuron rather than through a presynaptic mechanism,
since the actions of these drugs was dependent upon impulse flow in
the nigrostriatal dopamine neurons.

This conclusion was reached after

the cholinergic drugs, physostigmine and pilocarpine, and the anti¬
cholinergic drugs, atropine and benztropine,

failed to affect tyrosine

hydroxylase activity after the cessation of impulse flow in the dopa¬
minergic neurons with GBL, and after physostigmine and pilocarpine
were shown to increase the accumulation of Dopac in the striatum, an
indication of increased impulse flow in the nigro-neostriatal dopamine
neurons.

Based on previous work with intrastriatal injections of cho¬

linergic and anticholinergic drugs, which showed similar changes to
those found with the systemic use of these drugs in this study, it was
postulated that the site of action may be within the striatum and
mediated by a neuronal feedback to the dopaminergic nerve cell bodies
in the substantia nigra.

The possibility , however, of an extra-striatal

site of action for these drugs with a neuronal input system to the
substantia nigra cannot be ruled out by this study.

3.

6-Hydroxydopamine treated rats, used as a possible animal model

of Parkinson's Disease, responded in the same way as normal rats to
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benztropine, by decreasing tyrosine hydroxylase activity; however,
they were unable to increase tyrosine hydroxylase activity after
treatment with physostigmine, as normal rats did.

This inability to

increase dopaminergic activity in order to compensate for increased
cholinergic input was suggested as the explanation for the ability
of cholinergic drugs to exacerbate Parkinsonian extrapyramidal symptoms.

It therefore appears that there is a balance of dopaminergic cholinergic activity with respect to striatal impulse outflow, with
each of the systems not only under feedback regulation of their own
neurotransmitters, but also under the influence of each other’s acti¬
vity.

The cholinergic neurons are influenced by tonic inhibitory

dopaminergic activity, while the dopamine neurons are, in turn, affected
by stimulatory cholinergic activity, with all systems working to
maintain the proper dopaminergic - cholinergic balance within the
striatum.

48

BIBLIOGRAPHY

1.

Anden, N.E.,

"Antipsychotic Drugs and Catecholamine Synapses -

Summary", J. Psychiat. Res.

.

2

(1974),

11:97-104

Anden, N.E. and Bedard, P., "Influences of Cholinergic Mechanisms
on the Function and Turnover of Brain Dopamine", J. Pharm.
Pharmacol.

3.

(1971)

23:6:460-462

Anden, N.E., Corrodi, H., Fuxe, K., and Ungerstedt, U., "Impor¬
tance of Nervous Impulse Flow for the Neuroleptic Induced Increase
in Amine Turnover in Central Dopamine Neurons", Eur. J. Pharmacol.
(1971) 15:193-199

4.

Anden, N.E., Dahlstrom, A.,

Fuxe, K., and Larsson, K., "Functional

Role of the Nigro-Neostriatal Dopamine Neurons", Acta Pharmacol.
et Toxicol.

.

5

(1966)

24:263-274

Arnfred, T. and Randrup, A., "Cholinergic Mechanism in Brain
Inhibiting Amphetamine-Induced Stereotyped Behavior", Acta
Pharmacol, et Toxicol.

6.

Barbeau, Andre,

(1968) 26:384-394

"Biochemistry of Huntington's Chorea", Advances

in Neurology Vol. 1 (1973) Raven Press, N.Y., p. 473-516
7.

Barthollni, G. and Pletscher, A.,

"Atropine-Induced Changes of

Cerebral Dopamine Turnover", Experientla (1971)
8.

27:11:1302-1303

Barthollni, G. and Stadler, H., "Cholinergic and GABA-ergic
Influence on the Dopamine Release in Extrapyramidal Centers",
Chemical Tools in Catecholamine Research Vol. 2 (1975) NorthHolland/American Elsevier Publ. Co., p. 235-242

49

9.

Bowers, M.B. and Roth, R.H., "Interaction of Atropine-Like Drugs
with Dopamine-Containing Neurones in Rat Brain", Brit. J. Phar¬
macol.

10.

(1972) 44:2:301-306

Carlsson, A., "Dopaminergic Autoreceptors", Brit. J. Pharmacol.
(1974) 50:219-225

11.

Carpenter, Malcolm B.,

Core Text of Neuroanatomy,

(1974) Williams

& Wilkins Co., Baltimore, Md., p. 181-194
12.

Corrodi, H., Fuxe, K., and Lidbrink, P.,

"Interaction between

Cholinergic and Catecholaminergic Neurones in Rat Brain", Brain
Res.
13.

(1972)

43:2:397-416

Costall, B. and Naylor, R.J., "Cholinergic Modification of Ab¬
normal Involuntary Movements Induced in the Guinea Pig by Intrastriatal Dopamine", J. Pharm. Pharmacol.

14.

(1975)

27:273-275

Coyle, J.T. and Snyder, S.H., "Antiparkinsonian Drugs: Inhibition
of Dopamine Uptake in the Corpus Striatum as a Possible Mechanism
of Action", Science (1969) 166:907:899-901

15.

De la Torre, J.C.,

"Localization of Dopamine in Brain Following

Administration of L-DOPA and a Decarboxylase Inhibitor", Adv.
in Neurol. Vol. 2 (1973) Raven Press, N.Y., p. 59-77
16.

Dilbey, S.,

Catzias, G.C., Steck, A., and Papavasiiion, P.S.,

"Apomorphine Versus L-DOPA in Parkinsonism", Fed. Proc.

(1971)

30:216
17.

Farnebo, L.0., Fuxe, K., Hamberger, B., and Ljungdahl, H., "Effect
of Some Antiparkinsonian Drugs on Catecholamine Neurons",
Pharm. Pharmacol.

(1970)

22:10:733-737

.

50

18.

Frigyesi, T.L. and Purpura, D.P., "Electrophysiological Analysis
of Reciprocal Caudate-Nigral Relations", Brain Res.

(1967)

6:440-456
19.

Furchgott, R.F., Steinsland, O.S., and Wakade, T.D., "Studies
on Prejunctional Muscarinic and Nicotinic Receptors", Chemical
Tools in Catecholamine Research Vol. 2
American Elsevier Publ.

20.

Co., p.

(1975) North Holland/

167-174

Fuxe, K., Goldstein, M., and Ljungdahl, A., "Antiparkinsonian
Drugs and Central Dopamine Neurons", Life Sci.

21.

Fuxe, K. and Ungerstedt,

(1970) 9:1:811-824.

U., "Antiparkinsonian Drugs and Dopa¬

minergic Neostriatal Mechanisms", Pharmacol.

& Therap. Part B

(1976) 2:1:41-47
22.

Fuxe, K.

and Ungerstedt, U., "Studies on the Cholinergic and

Dopaminergic Innervation of the Neostriatum with the Help of
Intraneostriatal Injections of Drugs", Pharmacol.

& Therap.

Part B (1976) 2:1:29-36
23.

Goodman, L.S. and Gilman, A., The Pharmacological Basis of
Therapeutics, 5th ed.
pp. 227-239,

24.

(1975) MacMillan Publ. Co., Inc., N.Y.,

467-476, 514-532

Harris, J.E., Baldessarini, R.J.,and Roth, R.H., "Amphetamine
Induced Inhibition of Tyrosine Hydroxylation in Homogenates of
Rat Corpus Striatum", Neuropharm.

25.

(1975) 14:457-471

Haubrich, D.R. and Reid, W.D., "Effects of Pilocarpine or Arecoline Administration on Acetylcholine Levels and Serotonin Turnover
in Rat Brain", J. Pharmacol. Exp. Therap.

(1972) 181:1:19-27

51

26.

Hiley, C.R. and Burgen, A.S.V., "The Distribution of Muscarinic
Receptor Sites in the Nervous System of the Dog", J. Neurochem.
(1974) 22:159-162

27.

Hiley, C.R. and Miller, R.J.,

"Antimuscarinic Properties of Neuro

leptics and Drug-Induced Parkinsonism", Nature (1974) 248:596-597
28.

Holz, R.W. and Coyle, J.T., "The Effects of Various Salts, Tem¬
perature, and the Alkaloids Veratridine and Batrachotoxin on the
O

Uptake of JH-Dopamine into Synaptosomes from Rat Striatum",
Molec. Pharmacol.
29.

(1974) 10:746-758

Homykiewicz, 0., "Dopamine in the Basal Ganglia - It's Role and
Therapeutic Implications", Brit. Med. Bull.

30.

Homykiewicz, 0., "Mechanisms of Action of L-DOPA in Parkinsonism
Adv.

31.

in Neurol. Vol. 2

(1973) Raven Press, N.Y., p.

1-11

Homykiewicz, 0., "Parkinson's Disease: From Brain Homogenate
to Treatment", Fed. Proc.

32.

(1973) 29:172-178

(1973) 32:2:183-190

Javoy, F., Agid, Y., Bovet, D., and Glowinski, J., "Changes in
Neostriatal Dopamine Metabolism after Carbachol or Atropine
Microinjections into the Substantia Nigra", Brain Res.

(1974)

68:253-260
33.

Kehr, W., Carlsson, A., and Lindqvist, M., "A Method for the
Determination of 3,4-Dihydroxyphenylalanine
Naunyn-Schmiedeberg1s Arch. Pharmacol.

34.

(Dopa) in Brain",

(1972) 274:273-280

Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., Attack, C.,
"Evidence for a Receptor-Mediated Feedback Control of Striatal
Tyrosine Hydroxylase Activity", J. Pharm. Pharmacol.
24:744-747

(1972)

52

35.

Kelly, P.H. and Miller, R.J., "The Interaction of Neuroleptic
and Muscarinic Agents with Central Dopaminergic Systems", Brit.
J. Pharmacol.

36.

(1975) 54:1:115-121

McGeer, E.G., Fibiger, H.C., McGeer, P.L., and Brooke, S.,
"Temporal Changes in Amine Synthesizing Enzymes of Rat Extrapyramidal Structures after Hemitransections or 6-hydroxydopamine
Administration", Brain Res.

37.

(1973) 52:289-300

McGeer, P.L., McGeer, E.G., Fibiger, H.C., and Wickson, V. ,
"Neostriatal Choline acetylase and Cholinesterase following
Selective Brain Lesions", Brain Res.

38.

Miller, R.J. and Hiley, R., "Antimuscarinic Actions of Neuro¬
leptic Drugs", Adv. Neurol.

.

39

(1971) 35:308-314

(1975) 9:141-154

Murphy, G.F., Robinson, D., and Sharman, D.F., "The Effect of
Tropolone on the Formation of 3,4-dihydroxyphenylacetic acid in
the Brain of the Mouse", Brit. J. Pharmacol.

.

40

(1969) 36:107-115

Nose, T. and Takemoto, H., "Effect of Oxotremorine on HVA Con¬
centration in the Striatum of the Rat", Eur. J. Pharmacol.

(1974)

: :

25 1 51-55

.

41

O'Keefe, R., Sharman, D.F., and Vogt, M., "Effect of Drugs used
in Psychoses on Cerebral Dopamine Metabolism", Brit. J. Pharmacol.

(1970)
.

42

38:287-304

Olivier, A., Parent, A., Simard, H., and Poirer, L.J., "Cholin¬
esterase Striatopallidal and Striatonigral Efferents in the Cat
and the Monkey",

Brain Res.

(1970) 18:273-282

53

43.

Patrick, R.L., Snyder, T.E., and Barchas, J.D., "Regulation of
Dopamine Synthesis in Rat Brain Striatal Synaptosomes", Molec.
Pharmacol.

44.

(1974)

11:621-631

Perez-Cruet, J., Gessa, G., Tagliamonte, A., and Tagliamonte, P.,
"Evidence for a Balance in the Basal Ganglia between Cholinergic
and Dopaminergic Activity", Fed. Proc.

45.

(1971) 30:216

Porter, C.C., "Inhibitors of Aromatic Amino Acid Decarboxylase",
Adv. in Neurol. Vol. 2 (1973) Raven Press, N.Y., p.

46.

37-58

Roth, R.H. and Bunney, B.S., "Interaction of Cholinergic Neurons
with other Chemically Defined Neuronal Systems in the Central
Nervous System", Biology of Cholinergic Function (1976) Raven
Press, N.Y., p.

47.

379-394

Roth, R.H., Murrin, L.C., and Walters, J.R., "Central Dopaminergic
Neurons: Effects of Alterations in Impulse Flow on Accumulation
of Dihydroxyphenylacetic Acid", Europ. J. Pharmacol.

(1976)

36:1:163-171
48.

Roth, R.H., Walters, J.R., Murrin, L.C., and Morgenroth, V.H.,
"Dopamine Neurons: Role of Impulse Flow and Pre-Synaptic Receptors
in the Regulation of Tyrosine Hydroxylase", In Pre- and Postsynaptic
Receptors

49.

(1975) Marcel Dekker, Inc., p. 5-48

Schechter, M.D. and Rosecrans, J.A., "Behavioral Evidence for
Two Types of Cholinergic Receptors in the Central Nervous System",
Europ.

50.

J, Pharmacol.

(1971)

15:375-378

Shaywitz, B.A., Yager,R.D., and Klopper, J.H., "Selective Brain
Dopamine Depletion in Developing Rats: An Experimental Model of
Minimal Brain Dysfunction", Science

(1976) 191:305-308

54

51.

Shute, C.C.D. and Lewis, P.R., "The Ascending Cholinergic Reti¬
cular System: Neocortical, Olfactory, and Subcortical Projections",
Brain

52.

(1967) 90:497-520

Snyder, S.H., "Actions of Anticholinergic Drugs on Striatal
Dopamine", Pharmacol.

& Therap. Part B (1976) 2:1:65-70
3

53.

Snyder, S.H.

and Coyle, J.T., "Regional Differences in

Uptake into Rat Brain Homogenates", J. Pharmacol.

H-Dopamine

Exp. Therap.

(1969) 165:1:78-86
54.

Snyder, S.H., Greenberg, D., and Yamumura, H.I., "Anti¬
schizophrenic Drugs: Affinity for Muscarinic Cholinergic Receptor
Sites in the Brain Predicts Extrapyramidal Effects", J. Psychiat.
Res.

55.

(1974) 11:91-95

Sourkes, T.L., "Enzymology and Sites of Action of Monoamines in
the Central Nervous System", Adv.
Raven Press, N.Y., p.

56.

(1973)

13-36

Sourkes, T.L., "Parkinson's Disease and Other Disorders of the
Basal Ganglia", Med. Neurochem.

57.

in Neurol. Vol. 2

(1972) p. 565-578

Trabucchi, M., Cheney, K.L., Hanin, I., and Costa, E., "Appli¬
cation of Principles of Steady-State Kinetics to the Estimation
of Brain Acetylcholine Turnover Rate: Effects of Oxotremorine
and Physostigmine", J. Pharmacol. Exp. Therap.

58.

Ulus, I.H.

(1975) 194:1:57-64

and Wurtman, R.J., "Choline Administration: Activa¬

tion of Tyrosine Hydroxylase in Dopaminergic Neurons of Rat Brain",
Science (1976) 19^:1060-1061

55

59.

Walters, J.R. and Roth, R.H., "Dopaminergic Neurons: Drug-Induced
Antagonism of the Increase in Tyrosine Hydroxylase Activity
Produced by Cessation of Impulse Flow", J. Pharmacol. Exp. Therap.
(1974) 191:1:82-91

60.

Westfall, T.C., "Effect of Muscarinic Agonists on the Release
of

3

H-Norepinephrine and

3

H-Dopamine by Potassium and Electrical

Stimulation from Rat Brain Slices", Life Sci.
61.

(1974) 14:9:1641-1652

Van Woert, M.H., Ambani, L., and Bowers, M.B., "Levodopa and
Cholinergic Hypersensitivity in Parkinson’s Disease", Neurol.
Suppl.

62.

(May 1972) p.

86-93

Ziegler, H., Del Basso, P., and Longo, V.G., "Influence of 6Hydroxydopamine and of a-methy1-p-tyrosine on the Effects of
Some Centrally Acting Agents", Physiol.

63.

Behav.

(1972) 8:3:391-396

Zivkovic, B., Guidolti, A., Revuelta, A., and Costa, E., "Effect
of Thioridazine, Clozapine, and Other Antipsychotics on the
Kinetic State of Tyrosine Hydroxylase and on the Turnover Rate
of Dopamine in Striatum and Nucleus Accumbens", J. Pharmacol.
Exp. Therap.

(1975)

194:1:37-46

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

